Acute Myeloid Leukemia: How Do We Measure Success?

Area of Science:

• Hematology
• Oncology
• Clinical Trial Design

Background:

• Novel therapies for acute myeloid leukemia (AML) development and approval lag behind other cancers.
• Meaningful endpoints are critical for evaluating treatment success in AML drug development.
• Overall survival (OS) is the standard for regulatory approval but may not fully capture treatment benefits.

Purpose of the Study:

• To discuss various strategies for defining patient outcomes in AML.
• To highlight the challenges associated with different AML outcome measures.
• To inform the development of more effective AML therapies.

Main Methods:

• Literature review of clinical trial endpoints in AML.
• Analysis of regulatory approval criteria for AML treatments.
• Discussion of alternative outcome measures and their limitations.

Main Results:

• Overall survival (OS) remains the primary endpoint for regulatory approval in AML.
• Challenges exist in defining and measuring alternative endpoints like remission duration or quality of life.
• No single alternative endpoint has universally replaced OS for AML therapy approval.

Conclusions:

• Defining optimal endpoints for AML is crucial for accelerating the development of novel therapies.
• A multifaceted approach considering various outcome measures may be necessary.
• Further research is needed to validate and implement new endpoints in AML clinical trials.